These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29439151)

  • 21. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
    Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
    Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.
    Ribeiro D; Klarqvist MDR; Westermark UK; Oliynyk G; Dzieran J; Kock A; Savatier Banares C; Hertwig F; Johnsen JI; Fischer M; Kogner P; Lovén J; Arsenian Henriksson M
    Cell Rep; 2016 Jul; 16(4):979-993. PubMed ID: 27396325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
    Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
    Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
    O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
    BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.
    Maris JM
    Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200
    [No Abstract]   [Full Text] [Related]  

  • 30. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.
    Liu M; Xia Y; Ding J; Ye B; Zhao E; Choi JH; Alptekin A; Yan C; Dong Z; Huang S; Yang L; Cui H; Zha Y; Ding HF
    Cell Rep; 2016 Oct; 17(2):609-623. PubMed ID: 27705805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
    Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
    PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ZAR1 knockdown promotes the differentiation of human neuroblastoma cells by suppression of MYCN expression.
    Watanabe Y; Ishizuka Y; Hirano T; Nagasaki-Maeoka E; Hoshi R; Yoshizawa S; Uekusa S; Kawashima H; Sugito K; Shinohara K; Fukuda N; Nagase H; Soma M; Koshinaga T; Fujiwara K
    Med Oncol; 2017 Aug; 34(9):158. PubMed ID: 28791558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
    He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L
    Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306
    [No Abstract]   [Full Text] [Related]  

  • 37. Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.
    Yang L; Li Y; Wei Z; Chang X
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2341-2348. PubMed ID: 29247836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
    Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
    Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYCN-mediated murine cancer models.
    Althoff K; Schramm A
    Aging (Albany NY); 2017 Apr; 9(4):1084-1085. PubMed ID: 28377536
    [No Abstract]   [Full Text] [Related]  

  • 40. Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma.
    Helmsauer K; Valieva ME; Ali S; Chamorro González R; Schöpflin R; Röefzaad C; Bei Y; Dorado Garcia H; Rodriguez-Fos E; Puiggròs M; Kasack K; Haase K; Keskeny C; Chen CY; Kuschel LP; Euskirchen P; Heinrich V; Robson MI; Rosswog C; Toedling J; Szymansky A; Hertwig F; Fischer M; Torrents D; Eggert A; Schulte JH; Mundlos S; Henssen AG; Koche RP
    Nat Commun; 2020 Nov; 11(1):5823. PubMed ID: 33199677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.